中國生命集團(08296.HK)向中科臻慧增資 後者組合營從事投資活動
中國生命集團(08296.HK)公佈,間接全資附屬中科訊達與主席許建春持有之南嶽天車訂立增資協議,將中科臻慧之註冊資本由1,000萬元人民幣(下同),增至8,000萬元。
根據增資協議,中科訊達及南嶽天車同意以現金方式,分別向中科臻慧之註冊資本出資分別3,570萬元及3,430萬元,分別持有51%及49%股權。
另外,中科臻慧與合營夥伴訂立合營協議,據此,訂約雙方同意於中國共同成立主要從事投資活動及企業管理諮詢的合營公司。合營公司之註冊資本爲7,000萬元,,其中,中科臻慧及合營夥伴分別以現金方式出資4,000萬元及3,000萬元,分別佔合營公司股權約57.14%及42.86%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.